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The highly substrate-specific strictosidine syn-
thase (EC 4.3.3.2) catalyzes the biological
Pictet-Spengler condensation between trypt-
amine and secologanin, leading to the synthesis
of about 2000 monoterpenoid indole alkaloids in
higher plants. The crystal structure of Rauvolfia
serpentina strictosidine synthase (STR1) in
complex with strictosidine has been elucidated
here, allowing the rational site-directed muta-
tion of the active center of STR1 and resulting
in modulation of its substrate acceptance.
Here, we report on the rational redesign of STR1
by generation of a Val208Ala mutant, further de-
scribing the influence on substrate acceptance
and the enzyme-catalyzed synthesis of 10-
methyl- and 10-methoxystrictosidines. Based
on the addition of strictosidine to a crude
strictosidine glucosidase preparation from
Catharanthus cells, a combined chemoenzy-
matic approach to generating large alkaloid
libraries for future pharmacological screenings
is presented.
INTRODUCTION
The Pictet-Spengler condensation is a well known reac-
tion required for the chemical synthesis of alkaloids [1]
and represents the first dedicated step of indole alkaloid
biosynthesis (Figure 1). Characterization of this reaction
at the enzymatic level has so far been carried out for three
structurally diverse and therapeutically potent alkaloid
families. The first of these consists of about 6000 isoqui-
noline structures, including morphine and codeine; the
second is known as the monoterpenoid indole alkaloids,
comprising about 2000 structurally complex and impor-
tant members, including the anticancer agents vinblastine
and vincristine; the third is a small family that encom-
passes the monoterpenoid isoquinolines such as theChemistry & Biology 14, 979–emetic drug emetine. Strictosidine synthase catalyzes
the Pictet-Spengler condensation of tryptamine and seco-
loganin and represents one of the most highly character-
ized enzymes of alkaloid biosynthesis, as strictosidine
plays an important role as a central precursor in the bio-
synthesis of almost all plant monoterpenoid indole alka-
loids (Figure 1). Biochemical studies have clearly demon-
strated a pronounced substrate specificity and complete
enantioselectivity of the enzyme, leading exclusively to
3a-(S)-strictosidine [2].
Strictosidine synthase has been detected and bio-
chemically characterized from cell suspension cultures
of the Apocynaceae plant Catharanthus roseus [2, 3], the
Indian medicinal plant Rauvolfia serpentina [4], as well as
from the Rubiaceae Ophiorrhiza pumila [5]. The cDNA of
STR1 has been cloned from R. serpentina and has been
shown to be actively expressed in Escherichia coli, yeast,
and insect cells [6, 7]. Moreover, to our knowledge, it is the
first example of an enzyme involved in alkaloid biosynthe-
sis being overexpressed and purified in milligram quanti-
ties. Amino acid sequence comparison has yielded limited
information concerning the reaction mechanism and spe-
cific substrate acceptance of STR1. In order to analyze the
molecular structure of the synthase, the structure of the
native enzyme as well as its complexes with its natural
substrates tryptamine and secologanin have been re-
cently determined, providing the first, to our knowledge,
information on the active site and preliminary insight into
the mechanism of the synthase [8–10].
In order to design STR1 mutants that can accept various
derivatives of tryptamine and produce corresponding
strictosidine derivatives, we solved the crystal structure
of Rauvolfia-STR1 in complex with its product 3a-(S)-
strictosidine. Based on the structure obtained, we carried
out rational site-directed mutagenesis experiments; this
strategy provided the opportunity to modulate the sub-
strate specificity of STR1, with the aim to develop combi-
natorial biomimetic approaches for the generation of novel
and large alkaloid libraries, containing thousands of new
products, by engineering the wild-type enzyme. The cur-
rent paper thus describes the crystal structure of STR1
in complex with strictosidine and mutational studies for985, September 2007 ª2007 Elsevier Ltd All rights reserved 979
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Rational Engineering of Strictosidine SynthaseFigure 1. Strictosidine as the Central Intermediate in Indole Alkaloid Biosynthesis
Strictosidine synthase (STR1) catalyzes the enantioselective condensation of tryptamine and secologanin, leading to 3-a(S)-strictosidine—a central
reaction in the biosynthesis of the entire family of monoterpenoid indole alkaloids in plants.modulation of STR1 activity, exemplifying how a divergent
biomimetic approach can be used to generate large sets
of novel alkaloids. In addition, the structure of the enzyme
complex also provides information on residues interacting
with the remaining part of the strictosidine molecule,
which is important for the future generation of additional
enzyme mutants.
RESULTS AND DISCUSSION
Crystal Structure of the STR1-Strictosidine
Complex
The crystal structure of the native Rauvolfia-STR1 has
been previously solved [10]. The overall architecture of
STR1 resembles a six-bladed b propeller fold. All six
blades are radially arranged around a pseudo 6-fold-
symmetry axis, and each blade contains a twisted, four-
stranded antiparallel b sheet. The active site is located
near the pseudo 6-fold-symmetry axis (Figure 2A). The
crystal structure of STR1 in complex with strictosidine at
a resolution of 3.0 A˚ provides further detailed information
on the architecture of the active site (Figure 2A). As shown
in Figure 2B, the indole ring of the tryptamine unit is lo-
cated in the hydrophobic pocket, which is lined by 6 resi-
dues (Phe226, Val208, Val167, Trp149, Tyr151, including980 Chemistry & Biology 14, 979–985, September 2007 ª2007Gly210). The 5 hydrophobic residues are either invariant
or conservatively substituted by other hydrophobic amino
acids in the enzyme from different plant species.
The tryptamine part of the strictosidine molecule is
stacked between 2 aromatic residues, Tyr151 and
Phe226, which we have called the ‘‘indole sandwich.’’
The sandwich appears to play an important role in keeping
the indole ring in place via p-p interaction with the aro-
matic residues and via van der Waals interactions with
the 3 other hydrophobic amino acids, Val208, Val167,
and Trp149. All of these residues are conserved in pres-
ently known STR sequences (see the Supplemental Data
available with this article online). The latter three amino
acids shield the steric positions 10 and 11 of strictosidine
(5 and 6 positions, respectively, in tryptamine), in particu-
lar, the Val208 residue (Figure 2C). Tryptamine derivatives
with bulky groups at these positions therefore act as poor
substrates. In fact, four substrate specificity studies with
a number of putative tryptamine derivatives, performed
with strictosidine synthase from Catharanthus [3, 11] and
Rauvolfia [4, 10], underlined such an effect. Those trypt-
amine derivatives with relatively small substituents (fluoro,
hydroxyl) at these positions are, in principle, accepted,
whereas the substrate 6-methoxytryptamine showed
much lower transformation (2% relative enzyme activityElsevier Ltd All rights reserved
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Rational Engineering of Strictosidine SynthaseFigure 2. Strictosidine at the Active Site of STR1
(A) Ribbon diagram of the STR1-strictosidine complex. Each blade of the propeller is shown in a different color. The strictosidine is shown in ball and
stick.
(B) Stereo view of the strictosidine-binding site region of the STR1-strictosidine complex. Residues within 4 A˚ of strictosidine are shown in purple, and
strictosidine is shown in yellow. The (Fo  Fc) SIGMAA-weighted electron density of strictosidine contoured at 3.1 s is shown in green. The (Fo  Fc)
SIGMAA-weighted electron densities of Val208A and that of other hydrophobic residues around the indole part of the strictosidine molecule, con-
toured at 2 s, are shown in blue. Tyr151 and Phe226 represent the indole sandwich.
(C) 2D representation of the STR1-strictosidine complex highlighting Val208 and the hydrogen bond network in a distance of < 4.1 A˚.compared to tryptamine), and 5-methoxy- or 5-methyl-
tryptamine is not accepted by native STR1. Positions
5 and 6 of tryptamine seem to be, however, crucial for
pharmacological activity, and a number of valuable drugs,
such as vinblastine, vincristine, reserpine, or quinine,
harbor a methoxy group at these positions.
Mutational Studies forModulation of STR1 Activity
Based on the STR1-strictosidine complex, it was noted
that a methoxy group at the 5 position of tryptamine would
be in close proximity to Val208. In order to design a novel
STR1 mutant that can, in contrast to the wild-type, accept
5-methoxy- or 5-methyltryptamine as a substrate, the
bulky Val208 was replaced by Ala. The resulting mutant,
STR1-Val208Ala, exhibits conversion of 5-methoxy- and
5-methyltryptamine to the corresponding substituted
strictosidine (Table 1) in the presence of secologanin,
which was confirmed by using HPLC, LC-MS, 1H-, and
13C-NMR (Supplemental Data). Kinetic and turnover stud-
ies also showed more efficient conversion of 6-methyl-
and 6-methoxytryptamine by the mutant compared to
the native enzyme (Supplemental Data). Remarkably, the
KM value of 5-hydroxytryptamine is much lower for theChemistry & Biology 14, 979–9mutant than the wild-type STR1. For other mutants of
STR1, their activities, and their future use to generate an
expanded N-heteroyohimbine alkaloid library, see the
Supplemental Data.
Substitution of amino acid Val208 highlights the critical
role of this residue in substrate recognition at the indole
moiety of strictosidine (Table 1). A different approach (sat-
uration mutagenesis) with strictosidine synthase from
C. roseus also points to an important role for the
corresponding valine residue in substrate recognition
(S. O’Connor, personal communication). The new STR1
mutant Val208Ala retains its enantioselectivity. 1H-NMR
analysis of the 10-methylstrictosidine lactam-tetraacetate
obtained from methylated strictosidine by base-catalyzed
lactamization and acetylation showed that one of the four
acetyl signals was significantly shifted to a higher field
(1.18 ppm compared to the remaining three signals be-
tween 1.86 and 2.05 ppm, see Supplemental Data), clearly
indicating the 3a-(S)-configuration [2]. Moreover, the com-
plex structure of STR1-strictosidine provides knowledge
about residues interacting with the remaining part of stric-
tosidine, which is important for the design of mutants, and
takes the secologanin part into consideration.85, September 2007 ª2007 Elsevier Ltd All rights reserved 981
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Rational Engineering of Strictosidine SynthaseTable 1. Kinetic Data for Conversion of Tryptamine and Its 5- and 6-Substituted Derivatives for the Wild-Type and
Mutant STR1
Substrates Enzymes KM (mM) Kcat (s
1) Kcat/KM (mM
1s1)
Tryptamine Wild-type 0.072 (±0.02) 10.65 147.92
Val208Ala 0.219 (±0.04) 54.09 246.99
5-Methyl-tryptamine Wild-type n.d. — —
Val208Ala 0.281 (±0.13) 6.56 23.35
5-Methoxy-tryptamine Wild-type n.d. — —
Val208Ala 3.592 (±1.12) 79.66 22.18
6-Methyl-tryptamine Wild-type 0.393 (±0.17) 2.32 5.90
Val208Ala 0.762 (±0.21) 10.95 14.37
6-Methoxy-tryptamine Wild-type 0.962 (±0.15) 5.32 5.53
Val208Ala 0.307 (±0.01) 16.66 54.27
5-Fluoro-tryptamine Wild-type 0.259 (±0.10) 37.46 144.63
Val208Ala 1.302 (±0.13) 21.24 16.31
6-Fluoro-tryptamine Wild-type 0.136 (±0.05) 23.37 171.84
Val208Ala 0.356 (±0.09) 13.63 38.29
5-Hydroxy-tryptamine Wild-type 2.255 (±1.76) 562.14 249.29
Val208Ala 0.844 (±0.34) 18.12 21.47
Data are the average of 2–3 independent experiments. n.d. = not detectable.Chemoenzymatic Approach
Strictosidine and its derivatives are source material for
preparative structure modification. The enzyme that fol-
lows STR1 in the biosynthesis of the indole alkaloid family
is strictosidine glucosidase (SG). SG delivers the highly re-
active strictosidine aglycone that enters all the pathways
to the 2000 monoterpenoid indole alkaloids and, in addi-
tion, can serve as an efficient building block for biomimetic
generation of novel alkaloids [12, 13]. The biomimetic ap-
proach adopted here encompasses both the enzymatic
and chemical reactions in ‘‘one pot’’ (see Experimental
Procedures). It is based on the observation that, in the
presence of NH4
+ ions, N-heteroyohimbine alkaloids are
formed in enzyme assays [14]. The variability of this reac-
tion and the biochemical potential of reactive alkaloid
intermediates allows the insertion of various substituents
into the heteroyohimbine structure by way of a simple re-
action that can be systematically applied to preparative
structure modifications. The combinatorial approach has
proven to be successful with different substituted primary
amines (Figure 3) by using a crude enzyme extract from
C. roseus cell suspensions starting with strictosidine.
Cultivated Catharanthus cells synthesize a great number
of indole alkaloids [15] and exhibit significant expression
of SG. The versatility of this system is further exemplified
by the sole requirement of the SG enzyme, making it
theoretically possible to use any indole alkaloid-producing
cell system, including Rauvolfia. The approach can now
be significantly extended by STR1 and SG mutants from
R. serpentina, by using a combination of X-substituted982 Chemistry & Biology 14, 979–985, September 2007 ª2007tryptamine derivatives and various substituted primary
amines.
SIGNIFICANCE
The family of monoterpene indole alkaloids is charac-
terized by an enormous structural variety and a wide
range of pharmacological qualities. Several of them
have long-standing medical applications. Due to their
structural complexity, the extraction and isolation of
these alkaloids from plant material is very poor, but
purification from the natural source remains econom-
ically more efficient than total synthesis. The develop-
ment of new production strategies for alkaloids of
pharmaceutical interest is therefore a significant
objective. Moreover, the generation of novel alkaloid
derivatives is expected to deliver a higher number of
biologically valuable compounds.
In the current approach, an easily executable biomi-
metic concept is presented that allows the insertion of
various substitutions into the heteroyohimbine struc-
ture from a strictosidine starting point. The biochemi-
cal potential pertaining to reactive strictosidine aglyca
can be systematically used for preparative structure
modifications.
The crystal structure of STR1 in complex with its
product provides a structural understanding of the ob-
served substrate preference and its rational modula-
tion. With the STR1 mutant Val208Ala, we present
a re-engineered enzyme that, in contrast to a mutantElsevier Ltd All rights reserved
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Rational Engineering of Strictosidine SynthaseFigure 3. Chemoenzymatic Synthesis of Novel N-Analogous Heteroyohimbine Alkaloids
The illustrated combination of X with mono- and disubstitution and with R substitution (including R-X substitution) delivers thousands of new alkaloids
of the heteroyohimbine type. Each ‘‘one-pot’’ experiment leads to four diastereomeric alkaloids (at positions 19 and 20; residue R in brackets has not
yet been tested in the biomimetic approach).accepting secologanin analogs [16], now broadens
the substrate specificity for tryptamine derivatives
and thus the amount of strictosidine derivatives. Stric-
tosidine can be used as source material for further
chemoenzymatic modifications.
Based on this example, we show that calculation of
the substrate acceptance and engineering of novel
alkaloid derivatives is practicable for the indole part
of the strictosidine molecule and will be an attractive
strategy for the future generation of large libraries of
novel indole alkaloid analogs of potential biological
value.Chemistry & Biology 14, 979–9EXPERIMENTAL PROCEDURES
X-Ray Crystallography
The STR1 crystals were soaked for 10 min in a solution containing 25%
glycerol and 3 mM strictosidine prior to flash cooling at 100K in a liquid
nitrogen stream. X-ray data were collected by using synchrotron radi-
ation at the X13 beamline of European Molecular Biology Laboratory-
Hamburg. The complete data were collected to 3.0 A˚ resolution. The
data were processed by using the programs DENZO and SCALEPACK
[17]. The Rmerge at the highest-resolution bin is 75.8%, and one of the
reasons for the high value is that the data have 11.8-fold redundancy.
However, the I/s(I) at this bin is 3.7, and with this improved signal-to-
noise ratio, we used data to 3.0 A˚. As the data were nonisomorphous
with the native data, the structure of the STR1-strictosidine complex85, September 2007 ª2007 Elsevier Ltd All rights reserved 983
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Auto-Rickshaw, an automated crystal structure determination pipeline
[18]. The high-resolution structure of STR1 (PDB code: 1FP8) was used
as a search model. Within the pipeline, the program MOLREP [19] was
used for molecular replacement, and the rigid-body, positional, as well
as B factor refinement were performed by using the program CNS [20].
Strictosidine was built in the residual electron density by using the
graphics program COOT [21]. Subsequent refinement procedures
were carried out by using the program REFMAC5 [22] (see the data
collection and refinement statistics in the Supplemental Data).
‘‘One-Pot’’ Biomimetic Synthesis of N-Analogous Alkaloids
For a typical experiment, 100 mg (0.19 mmol) strictosidine—generated
as described previously [23]—was incubated in 3 ml 0.1 M KPi buffer
(pH 7.0) in the presence of 500 mg (3.1 mmol) tryptamine hydrochloride
(as primary amine compound) and 10 mg crude enzyme fromC. roseus
cell suspension at 30C for 5 hr. The resulting precipitation was sepa-
rated and dissolved immediately in 5 ml methanol and reduced by ex-
cess NaBH4 for 4 hr. The reaction mixture was diluted with 30 ml water
and extracted four times with ethyl acetate. The organic solvent was
combined and evaporated, and the remaining residue was purified
by preparative TLC in a chloroform-methanol-ammonia (100:3:0.1)
solvent system. The four possible C-19/C-20 stereoisomers were
identified with a molecular weight of 494 each; Rf values and yields
(%) were A, 0.77 (9); B, 0.72 (4); C, 0.58 (6); and D, 0.46 (16) (see the
Supplemental Data).
Supplemental Data
Supplemental data describing X-ray data collection statistics and re-
finement of the enzyme complex strictosidine synthase-strictosidine,
spectroscopic product identification (MS, NMR), determination of C-
3 stereochemistry of 10-methylstrictosidine, isolation of crude enzyme
for biomimetic synthesis and enzyme assay with purified STR1, the
turnover rate of STR1 wild-type compared to the mutant Val208Ala,
preparation of 10-methylstrictosidine (HPLC trace), sequence align-
ment of strictosidine synthase from different plant species, and data
on additional mutants are available at http://www.chembiol.com/cgi/
content/full/14/9/979/DC1/.
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